Xeris Biopharma Holdings, Inc. (XERS) Earnings History
Profitable10 years of earnings data (2016–2025) · Positive TTM net income
Loading earnings history...
Xeris Biopharma Holdings, Inc. (XERS) Earnings Overview
As of June 26, 2026, Xeris Biopharma Holdings, Inc. (XERS) reported trailing twelve-month net income of $12M, reflecting +100.9% year-over-year growth. The company earned $0.07 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, XERS's historical earnings data spans multiple years. The company achieved its highest annual net income of $554,000 in fiscal 2025, representing a new all-time high.
Xeris Biopharma Holdings, Inc. maintains positive profitability with a gross margin of 81.7%, operating margin of 8.5%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including LNTH ($279M net income, 15.2% margin), SUPN (-$29M net income, -5.4% margin), PAHC ($95M net income, 3.7% margin), XERS has room to improve margins relative to the peer group. Compare XERS vs LNTH →
XERS Earnings vs Peers
Earnings metrics vs comparable public companies
XERS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $554,000 | +101.0% | $25M | $0.00 | 0.2% | 8.5% |
| 2024 | -$55M | +11.9% | -$34M | $-0.37 | -27.0% | -16.6% |
| 2023 | -$62M | +34.2% | -$44M | $-0.45 | -38.0% | -26.8% |
| 2022 | -$95M | +22.9% | -$82M | $-0.70 | -85.9% | -74.3% |
| 2021 | -$123M | -34.7% | -$115M | $-1.55 | -247.5% | -232.2% |
| 2020 | -$91M | +27.4% | -$84M | $-2.14 | -446.0% | -408.8% |
| 2019 | -$126M | -109.0% | -$122M | $-3.49 | -4613.5% | -4496.0% |
| 2018 | -$60M | -126.3% | -$59M | $-4.99 | -2437.3% | -2407.5% |
| 2017 | -$27M | -101.0% | -$27M | $-13.09 | -1706.6% | -1711.4% |
| 2016 | -$13M | - | -$13M | $-7.17 | -1228.7% | -1230.8% |
Download Data
Export XERS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
What is XERS earnings per share (EPS)?
XERS trailing twelve-month (TTM) diluted EPS is $0.07, reflecting +100.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Xeris Biopharma Holdings, Inc.'s net income?
Xeris Biopharma Holdings, Inc. (XERS) trailing twelve-month net income is $12M as of 2025. Earnings grew +100.9% year-over-year.
Is XERS profitable?
Yes, XERS is profitable with a TTM net income of $12M and a net profit margin of +0.2%.
What is XERS's earnings growth rate?
XERS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are XERS's profit margins?
Xeris Biopharma Holdings, Inc. net profit margin is +0.2%, operating margin is +8.5%, and gross margin is +81.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is +4.0%.
Is XERS growing earnings?
Yes, XERS earnings are accelerating — EPS growth of +100.9% exceeds the 5-year CAGR of N/A. TTM net income reached $12M. Earnings momentum is strengthening.
What was XERS's best earnings year?
Xeris Biopharma Holdings, Inc.'s highest annual net income on record is $554000.00, achieved in fiscal year 2025. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were XERS's earnings last quarter?
XERS's most recent reported quarter was Q1 2026. Net income was $2M with diluted EPS of $0.01. For a full breakdown of all quarters, see the quarterly earnings table on this page.